Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Glitazones: clinical effects and molecular mechanisms.

Stumvoll M, Häring HU.

Ann Med. 2002;34(3):217-24. Review.

PMID:
12173692
2.

Thiazolidinediones -- some recent developments.

Stumvoll M.

Expert Opin Investig Drugs. 2003 Jul;12(7):1179-87. Review.

PMID:
12831352
3.

Insulin resistance and its treatment by thiazolidinediones.

Lebovitz HE, Banerji MA.

Recent Prog Horm Res. 2001;56:265-94. Review.

PMID:
11237217
4.

Troglitazone and related compounds: therapeutic potential beyond diabetes.

Fujiwara T, Horikoshi H.

Life Sci. 2000 Oct 6;67(20):2405-16. Review.

PMID:
11065164
5.

Metabolic and additional vascular effects of thiazolidinediones.

Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ.

Drugs. 2002;62(10):1463-80. Review.

PMID:
12093315
6.

[Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].

Dubois M, Vantyghem MC, Schoonjans K, Pattou F.

Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):511-23. Review. French.

PMID:
12527853
7.

The mode of action of thiazolidinediones.

Hauner H.

Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S10-5. Review.

PMID:
11921433
8.

Novel insulin sensitizers: pharmacogenomic aspects.

Otto C, Lehrke M, Göke B.

Pharmacogenomics. 2002 Jan;3(1):99-116. Review.

PMID:
11966407
9.

[Evaluation of a thiazolidinedione compound as a new antidiabetic drug].

Toyota T.

Nihon Rinsho. 2001 Nov;59(11):2211-8. Review. Japanese.

PMID:
11712410
10.

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

Diamant M, Heine RJ.

Drugs. 2003;63(13):1373-405. Review.

PMID:
12825962
11.

[Insulin sensitizer. A new therapy option for type 2 diabetic patients].

Filz HP.

MMW Fortschr Med. 2000 Sep 21;142(38):31-3. German.

PMID:
11050888
12.

[Mechanisms of action of thiazolidinediones].

Girard J.

Diabetes Metab. 2001 Apr;27(2 Pt 2):271-8. Review. French.

13.

[Glitazones (thiazolidinedione)].

Ducobu J, Sternon J.

Rev Med Brux. 2000 Oct;21(5):441-6. Review. French.

PMID:
11109896
14.

[Rosiglitazone (BRL-49653)].

Kameda N, Okuya S, Oka Y.

Nihon Rinsho. 2000 Feb;58(2):401-4. Review. Japanese.

PMID:
10707565
15.

The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.

Shimaya A, Kurosaki E, Nakano R, Hirayama R, Shibasaki M, Shikama H.

Metabolism. 2000 Mar;49(3):411-7.

PMID:
10726922
16.

Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.

Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, Tufari SR, Veerkamp JH, Vidal-Puig A, Henry RR.

J Clin Endocrinol Metab. 1998 Aug;83(8):2830-5.

PMID:
9709955
17.

Thiazolidinediones--tools for the research of metabolic syndrome X.

Komers R, Vrána A.

Physiol Res. 1998;47(4):215-25. Review.

18.

Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.

Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye JM, Sauerberg P, Wassermann K.

Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E841-54.

19.

Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.

Kurosaki E, Nakano R, Shimaya A, Yoshida S, Ida M, Suzuki T, Shibasaki M, Shikama H.

Biochem Pharmacol. 2003 Mar 1;65(5):795-805.

PMID:
12628477
20.

Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.

Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU.

Diabetes. 2003 Sep;52(9):2331-7.

Items per page

Supplemental Content

Support Center